5 Recommendations for data collection
5.1 Proposals for further data collection in the Cancer Drugs Fund include:
-
proportion of people having pembrolizumab who have an allogenic stem cell transplant
-
time to allogenic stem cell transplant
-
duration of treatment with pembrolizumab before allogenic stem cell transplant
-
long-term follow-up of people having pembrolizumab with or without subsequent allogenic stem cell transplant (in particular, collection of data on overall survival).